Chemotherapy of large bowel cancer.

Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg (1984) 3.96

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ (1993) 3.26

Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg (1984) 1.23

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. Br J Cancer (1990) 0.84

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. Br J Cancer (1985) 0.82

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. J Exp Clin Cancer Res (2009) 0.75

Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 2.73

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol (2001) 1.84

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A (1998) 1.81

CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine (2000) 1.80

Five-drug therapy for advanced breast cancer: a phase I study. Cancer Chemother Rep (1971) 1.77

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine (2004) 1.71

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A (1998) 1.70

Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 1.65

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A (1995) 1.60

The role of CpG dinucleotides in DNA vaccines. Trends Microbiol (1998) 1.57

Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology (2000) 1.49

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol (1998) 1.48

Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48

The utility of verbal autopsies for identifying HIV-1-related deaths in Haitian children. AIDS (1993) 1.34

Intrahepatic arterial infusion with 5-fluorouracil. Cancer (1971) 1.27

Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med (1999) 1.22

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine (2000) 1.22

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 1.20

CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 1.19

Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16

Trophic effect of ciliary neurotrophic factor on denervated skeletal muscle. Cell (1994) 1.14

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis (2008) 1.13

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A (1996) 1.11

Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. J Surg Oncol (1995) 1.08

Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treat Rep (1979) 1.07

CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol (2001) 1.06

Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther (2001) 1.01

The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine (2001) 0.97

Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol (1976) 0.97

Adriamycin cardiotoxicity in children: case reports, literature review, and risk factors. Cancer (1977) 0.96

CpG DNA as mucosal adjuvant. Vaccine (1999) 0.96

Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol (2001) 0.95

The role of antitumor antibiotics in current oncologic practice. Cancer Chemother Pharmacol (1978) 0.95

Doxorubicin toxicity. Onycholysis, plantar callus formation, and epidermolysis. JAMA (1975) 0.94

CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine (2000) 0.93

The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol (2001) 0.93

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci (1995) 0.93

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine (2001) 0.93

Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev (1998) 0.92

Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther (2001) 0.91

The Piromen test: a useful assay of bone marrow granulocyte reserves. Curr Ther Res Clin Exp (1969) 0.91

Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology (2001) 0.91

Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med (1998) 0.90

Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol Med (2000) 0.89

DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clin Immunol Immunopathol (1995) 0.89

Triple drug therapy in testicular tumors. Cancer (1969) 0.89

Breast carcinoma metastatic to the stomach. Report of a case in a male and review of an autopsy series. Am J Dig Dis (1968) 0.88

Application of DNA vaccine technology to aquaculture. Adv Drug Deliv Rev (2000) 0.88

Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol (1998) 0.88

Acute leukemia complicating metastatic breast cancer. Cancer (1973) 0.88

Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther (2001) 0.87

Coumarin-induced skin necrosis in a sixteen-year-old girl. Am J Cardiol (1969) 0.87

Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene. Hum Mol Genet (1996) 0.87

Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability. Gene Ther (1997) 0.87

Procoagulant and nerve-blocking effects of DMSO. Ann N Y Acad Sci (1967) 0.87

Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis (1992) 0.86

The role of CpG in DNA vaccines. Springer Semin Immunopathol (2000) 0.85

Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis. Oligonucleotides (2005) 0.85

Genetic vaccination of rainbow trout against viral haemorrhagic septicaemia virus: small amounts of plasmid DNA protect against a heterologous serotype. Virus Res (1999) 0.85

Effect of nerve extract of atrophy of denervated or immobilized muscles. Exp Neurol (1981) 0.84

The necessity of drug level monitoring in anticonvulsant drug therapy. Can J Physiol Pharmacol (1976) 0.84

Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms. Gene Ther (2001) 0.83

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol (2001) 0.83

Hypercalcemia complicating breast cancer. Clinical features and management. Oncology (1973) 0.83

Neurotrophic effects of sciatic nerve extract on denervated extensor digitorum longus muscle in the rat. Exp Neurol (1980) 0.83

Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. Cancer Treat Rep (1977) 0.82

Characteristics of hospitalized tuberculous patients today. South Med J (1978) 0.82

Hemangiopericytoma of the bladder after polyvinyl alcohol exposure. Cancer (1977) 0.81

Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer Treat Rep (1982) 0.81

Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. Cancer Treat Rep (1983) 0.81

Review of local soft tissue recurrence of breast cancer irradiated with and without actinomycin-D. Cancer (1977) 0.81

Optimization strategies for DNA vaccines. Intervirology (2000) 0.80

Epileptiform seizures in domestic fowl. VI. Plasma phenobarbital concentrations and anticonvulsant activity. Can J Physiol Pharmacol (1977) 0.80

Effect of denervation and nerve extract on ultrastructure of muscle. Exp Neurol (1988) 0.80

Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer (1974) 0.80

Partial purification from mammalian peripheral nerve of a trophic factor that ameliorates atrophy of denervated muscle. Exp Neurol (1985) 0.79

Pharmacological and biochemical studies in epileptic fowl. Fed Proc (1979) 0.79

Evaluating work performance. Am J Clin Nutr (1971) 0.79

Emergence of acute non-lymphocytic leukemia in breast cancer patients. Am J Med Sci (1982) 0.79

Analysis of adjuvant therapy in large bowel cancer. Cancer Clin Trials (1978) 0.79

Novel strategies using DNA for the induction of mucosal immunity. Crit Rev Immunol (1999) 0.78

Five-drug therapy in advanced breast cancer: factors influencing toxicity and response. Cancer (1974) 0.78

Effects of tumor cell viability and inoculum density on growth parameters in the human tumor, soft-agar clonogenic assay. Cancer Res (1988) 0.78

Intramuscular injection of DNA vaccines in fish. Methods Mol Med (2000) 0.78

The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Investig Drugs (2001) 0.77

Improved theophylline serum analysis by an appropriate internal standard for gas chromatography. J Chromatogr (1976) 0.77

Mucosal immunization with DNA vaccines. Microbes Infect (1999) 0.77

Effect of denervation and injected nerve extract on soluble proteins of extensor digitorum longus muscles of rats. Exp Neurol (1987) 0.77

Prevention of denervation atrophy in muscle: mammalian neurotrophic factor is not transferrin. Brain Res (1984) 0.76

History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord (2001) 0.76

External-beam radiation for carcinoma of the prostate. Eur Urol (1990) 0.76

Current cooperative clinical trials in the non-Hodgkin's lymphomas. Cancer Treat Rep (1977) 0.76

Phase I trial of ICRF-187 by 48-hour continuous infusion. Cancer Treat Rep (1981) 0.76

Trophic action of nerve extract on denervated skeletal muscle in vivo: dose dependency, species specificity, and timing of treatment. Exp Neurol (1983) 0.76

Tryptophan metabolism in breast cancer. Correlation with urinary steroid excretion. Cancer (1973) 0.75

Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer Res (1982) 0.75

Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev (1998) 0.75